HealthClot

Relapsed Refractory Multiple Myeloma | Current Treatment Options | Options on the Horizon In the first portion, hosted by Nina Shah, MD, Professor of Clinical Medicine, Multiple Myeloma Translational Initiative, Division of Hematology-Oncology, University of California San Francisco, San Francisco,…

Everything to Know About Blood Cancer | Dr. Deepankar Bhattacharya | Medanta Blood cancer is defined as the cancer of blood-forming tissues, hindering the body’s ability to fight infection. A type of blood cancer, leukaemia, includes bone marrow as well….

Multiple Myeloma Treatment | Blood Disorder Treatment in India #multiplemyeloma #blooddisorder #bonemarrowtransplant Ms Ann visited from Lagos, Nigeria for Multiple Myeloma Treatment. She was struggling for a very long time with lot of pains and other medical issues. Medsurge India…

Challenges and future perspectives for minimal residual disease (MRD) in multiple myeloma Irene Ghobrial, MD from Dana-Farber Cancer Institute, Boston, MA, chairs a discussion on the detection of minimal residual disease (MRD) in multiple myeloma (MM) patients during the 2017…

MM & Plasma cell dyscrasia

Benefits of alnuctamab in the treatment of R/R multiple myeloma Claudio Cerchione, MD, PhD, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy, outlines the advantages of the alnuctamab (formerly CC-93269), a novel BCMAxCD3…

The Multiple Myeloma Research Foundation – The Future The MMRF has made precision medicine a reality for multiple myeloma patients and the entire cancer community. It’s now time to take the next leap toward a cure.

Determining Staging and Risk in Multiple Myeloma C. Ola Landgren, MD, explains important factors he uses to determine staging and risk stratification to his patient, Aurora Torres, who has multiple myeloma. View more at http://curetoday.com/ CURE: Combining science and humanity…

The recent FDA approval of teclistamab for R/R multiple myeloma In this video, Bruno Paiva, PhD, University of Navarra, Pamplona, Spain, comments on the recent FDA approval of teclistamab, a bispecific BCMA-directed CD3 T-cell engager, for patients with relapsed/refractory (R/R)…

This is Blood Cancer This is blood cancer is a programme produced by Blood Cancer UK and ITN Productions which aims to shine a light on the disease and explore how together, we’re going to improve the lives of all…